Check out our HCV content
The addition of the two latest treatment regimens for hepatitis C essentially closes the circle on treatment of this disease. Don’t shorten therapy for older, sicker cellulitis patients, apixaban and rivaroxaban reversal agent gets FDA approval, and do black women pay a price for hair care products?
Listen to the MDedge Daily News podcast for all the details on today’s top news.
October 15, 2018
October 1, 2018
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.